Cargando…
Safety and Efficacy of Concurrent or Sequential Radiotherapy Plus (PD-1) Inhibitors in Oligometastatic Esophageal Cancer
PURPOSE: We assess real-world outcomes, including safety and efficacy, of concurrent or sequential treatment with radiotherapy plus programmed cell death protein 1 (PD-1) inhibitors in patients with oligometastatic esophageal cancer (OMEC). METHODS: This cohort study retrospectively collected clinic...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9849787/ https://www.ncbi.nlm.nih.gov/pubmed/36685716 http://dx.doi.org/10.2147/CMAR.S391529 |
_version_ | 1784872028570910720 |
---|---|
author | Duan, Yanan Qin, Wenru Yang, Linlin Zou, Bing Qie, Wenting Song, Ruiting Xue, Lu Wang, Linlin |
author_facet | Duan, Yanan Qin, Wenru Yang, Linlin Zou, Bing Qie, Wenting Song, Ruiting Xue, Lu Wang, Linlin |
author_sort | Duan, Yanan |
collection | PubMed |
description | PURPOSE: We assess real-world outcomes, including safety and efficacy, of concurrent or sequential treatment with radiotherapy plus programmed cell death protein 1 (PD-1) inhibitors in patients with oligometastatic esophageal cancer (OMEC). METHODS: This cohort study retrospectively collected clinical data of patients with synchronous or metachronous OMEC. All patients underwent concurrent or sequential treatment with radiotherapy plus PD-1 inhibitors. Each patient had up to five measurable metastatic lesions and up to three organs involved. Study endpoints were progression-free survival (PFS), treatment-related toxicities, locoregional progression-free survival (LRPFS), objective response rate (ORR), and disease control rate (DCR). Description statistics and Kaplan–Meier models were used for statistical analysis. RESULTS: A total of 86 patients were included, most of whom were diagnosed with squamous cell carcinoma histology (98%) and presented with synchronous OMEC (64%). The median follow-up period was 17 months (range: 6–32 months), the median PFS was 15.2 months (95% confidence interval: 12.1–18.2 months); and the 1- and 2-year PFS rates were 61.4% and 26.7%, respectively. The 1- and 2-year LRPFS were 91.3% and 57.3%, respectively. The ORR and DCR were 46.5% and 91.8%, respectively. Forty-two patients (48.8%) experienced grade 3 or higher treatment-related adverse events (TRAEs); a grade 5 treatment-related adverse event was observed in one patient (1.2%) who died of immune-related pneumonitis. CONCLUSION: Combining radiotherapy with PD-1 inhibitors is a safe and effective treatment option for patients with OMEC. No new safety concerns were identified in this study. However, due to the potential risk of cumulative toxicity, an individual risk-benefit assessment for each patient is required prior to treatment initiation. |
format | Online Article Text |
id | pubmed-9849787 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-98497872023-01-20 Safety and Efficacy of Concurrent or Sequential Radiotherapy Plus (PD-1) Inhibitors in Oligometastatic Esophageal Cancer Duan, Yanan Qin, Wenru Yang, Linlin Zou, Bing Qie, Wenting Song, Ruiting Xue, Lu Wang, Linlin Cancer Manag Res Original Research PURPOSE: We assess real-world outcomes, including safety and efficacy, of concurrent or sequential treatment with radiotherapy plus programmed cell death protein 1 (PD-1) inhibitors in patients with oligometastatic esophageal cancer (OMEC). METHODS: This cohort study retrospectively collected clinical data of patients with synchronous or metachronous OMEC. All patients underwent concurrent or sequential treatment with radiotherapy plus PD-1 inhibitors. Each patient had up to five measurable metastatic lesions and up to three organs involved. Study endpoints were progression-free survival (PFS), treatment-related toxicities, locoregional progression-free survival (LRPFS), objective response rate (ORR), and disease control rate (DCR). Description statistics and Kaplan–Meier models were used for statistical analysis. RESULTS: A total of 86 patients were included, most of whom were diagnosed with squamous cell carcinoma histology (98%) and presented with synchronous OMEC (64%). The median follow-up period was 17 months (range: 6–32 months), the median PFS was 15.2 months (95% confidence interval: 12.1–18.2 months); and the 1- and 2-year PFS rates were 61.4% and 26.7%, respectively. The 1- and 2-year LRPFS were 91.3% and 57.3%, respectively. The ORR and DCR were 46.5% and 91.8%, respectively. Forty-two patients (48.8%) experienced grade 3 or higher treatment-related adverse events (TRAEs); a grade 5 treatment-related adverse event was observed in one patient (1.2%) who died of immune-related pneumonitis. CONCLUSION: Combining radiotherapy with PD-1 inhibitors is a safe and effective treatment option for patients with OMEC. No new safety concerns were identified in this study. However, due to the potential risk of cumulative toxicity, an individual risk-benefit assessment for each patient is required prior to treatment initiation. Dove 2023-01-14 /pmc/articles/PMC9849787/ /pubmed/36685716 http://dx.doi.org/10.2147/CMAR.S391529 Text en © 2023 Duan et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Duan, Yanan Qin, Wenru Yang, Linlin Zou, Bing Qie, Wenting Song, Ruiting Xue, Lu Wang, Linlin Safety and Efficacy of Concurrent or Sequential Radiotherapy Plus (PD-1) Inhibitors in Oligometastatic Esophageal Cancer |
title | Safety and Efficacy of Concurrent or Sequential Radiotherapy Plus (PD-1) Inhibitors in Oligometastatic Esophageal Cancer |
title_full | Safety and Efficacy of Concurrent or Sequential Radiotherapy Plus (PD-1) Inhibitors in Oligometastatic Esophageal Cancer |
title_fullStr | Safety and Efficacy of Concurrent or Sequential Radiotherapy Plus (PD-1) Inhibitors in Oligometastatic Esophageal Cancer |
title_full_unstemmed | Safety and Efficacy of Concurrent or Sequential Radiotherapy Plus (PD-1) Inhibitors in Oligometastatic Esophageal Cancer |
title_short | Safety and Efficacy of Concurrent or Sequential Radiotherapy Plus (PD-1) Inhibitors in Oligometastatic Esophageal Cancer |
title_sort | safety and efficacy of concurrent or sequential radiotherapy plus (pd-1) inhibitors in oligometastatic esophageal cancer |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9849787/ https://www.ncbi.nlm.nih.gov/pubmed/36685716 http://dx.doi.org/10.2147/CMAR.S391529 |
work_keys_str_mv | AT duanyanan safetyandefficacyofconcurrentorsequentialradiotherapypluspd1inhibitorsinoligometastaticesophagealcancer AT qinwenru safetyandefficacyofconcurrentorsequentialradiotherapypluspd1inhibitorsinoligometastaticesophagealcancer AT yanglinlin safetyandefficacyofconcurrentorsequentialradiotherapypluspd1inhibitorsinoligometastaticesophagealcancer AT zoubing safetyandefficacyofconcurrentorsequentialradiotherapypluspd1inhibitorsinoligometastaticesophagealcancer AT qiewenting safetyandefficacyofconcurrentorsequentialradiotherapypluspd1inhibitorsinoligometastaticesophagealcancer AT songruiting safetyandefficacyofconcurrentorsequentialradiotherapypluspd1inhibitorsinoligometastaticesophagealcancer AT xuelu safetyandefficacyofconcurrentorsequentialradiotherapypluspd1inhibitorsinoligometastaticesophagealcancer AT wanglinlin safetyandefficacyofconcurrentorsequentialradiotherapypluspd1inhibitorsinoligometastaticesophagealcancer |